Savara Inc (NASDAQ:SVRA) Shares Acquired by Jennison Associates LLC

Jennison Associates LLC lifted its stake in shares of Savara Inc (NASDAQ:SVRA) by 128.0% during the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 8,815,358 shares of the company’s stock after purchasing an additional 4,948,596 shares during the quarter. Jennison Associates LLC owned about 6.51% of Savara worth $41,432,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also made changes to their positions in SVRA. SG Americas Securities LLC acquired a new position in shares of Savara during the 3rd quarter worth $140,000. Bank of New York Mellon Corp grew its stake in shares of Savara by 20.6% during the 3rd quarter. Bank of New York Mellon Corp now owns 261,435 shares of the company’s stock worth $988,000 after purchasing an additional 44,641 shares during the period. Principal Financial Group Inc. acquired a new position in shares of Savara during the 3rd quarter worth $48,000. Jump Financial LLC acquired a new position in shares of Savara during the 3rd quarter worth $123,000. Finally, Kestra Private Wealth Services LLC purchased a new stake in shares of Savara in the 3rd quarter worth about $64,000. 87.93% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

Several equities research analysts recently commented on SVRA shares. JMP Securities reiterated a “market outperform” rating and issued a $8.00 price objective on shares of Savara in a research report on Thursday, April 18th. Piper Sandler boosted their price objective on shares of Savara from $7.00 to $16.00 and gave the stock an “overweight” rating in a research report on Monday, March 4th. Five analysts have rated the stock with a buy rating, According to data from MarketBeat, Savara has a consensus rating of “Buy” and a consensus price target of $8.20.

Savara Price Performance

NASDAQ:SVRA opened at $4.69 on Wednesday. The firm has a market cap of $647.92 million, a price-to-earnings ratio of -14.21 and a beta of 0.77. The company has a current ratio of 15.66, a quick ratio of 15.66 and a debt-to-equity ratio of 0.19. The company’s 50-day moving average is $4.96 and its two-hundred day moving average is $4.42. Savara Inc has a 12-month low of $1.76 and a 12-month high of $5.70.

Savara (NASDAQ:SVRA) last released its earnings results on Thursday, March 7th. The company reported ($0.09) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.11) by $0.02. Research analysts expect that Savara Inc will post -0.38 EPS for the current year.

Savara Company Profile

Savara Inc, formerly Mast Therapeutics, Inc, is a clinical-stage pharmaceutical company. The Company is focused on the development and commercialization of novel therapies for the treatment of patients with rare respiratory diseases. Its pipeline includes AeroVanc, Molgradex and AIR001. AeroVanc is an inhaled formulation of vancomycin, which the Company is developing for the treatment of persistent methicillin-resistant Staphylococcus aureus, lung infection in cystic fibrosis patients.